• Adicet Bio to Participate in Upcoming Investor Conferences

    来源: Nasdaq GlobeNewswire / 07 1月 2021 07:00:00   America/New_York

    MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that company management will participate in two virtual investor conferences in January.

    Details of the events are as follows:

    H.C. Wainwright Bioconnect 2021 Conference
    The presentation will be available for on-demand viewing starting January 11, 2021 at 6:00 AM ET.

    B. Riley Securities' Oncology Investor Conference
    Fireside chat on January 20, 2021 at 3:30 PM ET.

    A replay of the pre-recorded H.C. Wainwright presentation can be accessed on January 11, 2021 in the investors section of the Company’s website, and a live webcast of the B. Riley presentation can be accessed in the same section of the Company’s website. 

    About Adicet Bio, Inc.

    Adicet Bio, Inc. is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

    Adicet Bio., Inc.
    Investor and Media Contacts
    Anne Bowdidge
    abowdidge@adicetbio.com

    Janhavi Mohite
    Stern Investor Relations, Inc.
    212-362-1200
    janhavi.mohite@sternir.com

     


    Primary Logo

分享